Ascher Shmulewitz1, Adi Zuloff-Shani2, Oz Adler3, 1 Chairman and CEO, Therapix Biosciences, NA, Tel-Aviv, Israel, 2 CTO, Therapix Biosciences, R&D, Tel-Aviv, Israel, 3 CFO, Therapix Biosciences, Finance, Tel-Aviv, Israel

- **Investment Rational**
  Therapix Biosciences is a clinical-stage, pharmaceutical company, NASDAQ traded, developing cannabinoid-based solutions to address unmet needs such as pain, Tourette syndrome (TS) and Obstructive Sleep Apnea (OSA). Therapix's aim is to connect cannabinoids to the healthcare system to improve the health and well-being of patients. Therapix is led by an experienced team of Senior Executives and Scientists. Market opportunity is $88.5B.

- **Business Strategy**
  Our strategy is creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals with accelerated pipeline programs including 505(b)2 and ODD. Therapix's IP portfolio consists of 12 patent families. In addition, we are operating to make our technology available as a nutraceutical to the medical cannabis market.

- **Core Technology**
  Therapix's proprietary platform technology is based on the "Entourage Effect" combining any cannabinoid with CannAmide™ to create a synergy. CannAmide™ is a Formulation of Pharma-grade Palmitoylethanolamide (PEA), an endocannabinoid-analog with a broad spectrum of pharmacological properties. Additionally, Therapix develops THX-160, a novel pharmaceutical preparation containing a CB2 Receptor agonist, synthesized by Raphael Mechoulam for the treatment of pain.

- **Product Profile/Pipeline**
  THX-110 a platform technology containing THC and CannAmide™ for treatment of TS and OSA. A phase Iia clinical study using THX-110 for TS successfully completed at Yale University. Phase IIb study initiated in Germany. OSA phase Ila study is ongoing in Assuta with topline results expected in 2019. THX-160 is in pre-clinical phase and preparations for pre-IND meeting are in-progress.

- **What's Next?**
  For THX-110 platform, Therapix's is currently preparing for phase III study under IND in TS and phase IIb study in OSA. For THX-160 we intend to explore the compound MoA and perform dose ranging studies. Additionally, tech transfer and upscaling of the compound are planned.